Punicalagin, a PTP1B inhibitor, induces M2c phenotype polarization via up-regulation of HO-1 in murine macrophages

Free Radic Biol Med. 2017 Sep:110:408-420. doi: 10.1016/j.freeradbiomed.2017.06.014. Epub 2017 Jul 8.

Abstract

Current data have shown that punicalagin (PUN), an ellagitannin isolated from pomegranate, possesses anti-inflammatory and anti-oxidant properties; however, its direct targets have not yet been reported. This is the first report that PTP1B serves as a direct target of PUN, with IC50 value of 1.04μM. Results from NPOI further showed that the Kon and Koff of PUN-PTP1B complex were 3.38e2M-1s-1 and 4.13e-3s-1, respectively. The active site Arg24 of PTP1B was identified as a key binding site of PUN by computation simulation and point mutation. Moreover, inhibition of PTP1B by PUN promoted an M2c-like macrophage polarization and enhanced anti-inflammatory cytokines expression, including IL-10 and M-CSF. Based on gene expression profile, we elucidated that PUN treatment significantly up-regulated 275 genes and down-regulated 1059 genes. M1-like macrophage marker genes, such as Tlr4, Irf1/2, Hmgb1, and Stat1 were down-regulated, while M2 marker genes, including Tmem171, Gpr35, Csf1, Il1rn, Cebpb, Fos, Vegfα, Slc11a1, and Bhlhe40 were up-regulated in PUN-treated macrophages. Hmox-1, a gene encoding HO-1 protein, was preferentially expressed with 16-fold change. Inhibition of HO-1 obviously restored PUN-induced M2 polarization and IL-10 secretion. In addition, phosphorylation of both Akt and STAT3 contributed to PUN-induced HO-1 expression. This study provided new insights into the mechanisms of PUN-mediated anti-inflammatory and anti-oxidant activities and provided new therapeutic strategies for inflammatory diseases.

Keywords: HO-1; M2 polarization; Murine; PTP1B; Punicalagin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Antioxidants / pharmacology*
  • Cell Differentiation / drug effects
  • Enzyme Inhibitors / pharmacology*
  • Gene Expression Profiling
  • Gene Expression Regulation
  • Heme Oxygenase-1 / genetics*
  • Heme Oxygenase-1 / metabolism
  • Hydrolyzable Tannins / pharmacology*
  • Interleukin-10 / genetics
  • Interleukin-10 / metabolism
  • Lipopolysaccharides / antagonists & inhibitors
  • Lipopolysaccharides / pharmacology
  • Membrane Proteins / agonists
  • Membrane Proteins / genetics*
  • Membrane Proteins / metabolism
  • Mice
  • Oxidative Stress
  • Phosphorylation / drug effects
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1 / antagonists & inhibitors
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1 / genetics*
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1 / metabolism
  • Proto-Oncogene Proteins c-akt / genetics
  • Proto-Oncogene Proteins c-akt / metabolism
  • RAW 264.7 Cells
  • STAT3 Transcription Factor / genetics
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Enzyme Inhibitors
  • Hydrolyzable Tannins
  • IL10 protein, mouse
  • Lipopolysaccharides
  • Membrane Proteins
  • STAT3 Transcription Factor
  • Stat3 protein, mouse
  • Interleukin-10
  • punicalagin
  • Heme Oxygenase-1
  • Hmox1 protein, mouse
  • Proto-Oncogene Proteins c-akt
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1
  • Ptpn1 protein, mouse